COMMUNIQUÉS West-GlobeNewswire

A Race Against Blindness Launches “Ultimate Ford Garage” Fundraiser With Two Ford Vehicles Plus $40,000 Cash
21/09/2026
Unexpected second chance brings the custom F-150 Raptor and Ford Explorer ST together in one $165,000 prize package supporting research for inherited retinal diseases GILBERT, Ariz., Sept. 21, 2026 (GLOBE NEWSWIRE) -- A [...]
LA Limited Addition Drumline, Breast Cancer Prevention Advocates Join Actress Dionne Lea and Renowned Breast Cancer Surgeon Dr. Kristi Funk to Rally in View Park to “Beat” Breast Cancer
21/09/2026
LOS ANGELES, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Breast cancer prevention advocates, nutrition experts, and community members will gather for a special Let’s Beat Breast Cancer rally from 1 to 3 p.m. on Sunday, Sept. 27 [...]
Le KFSH figure dans le classement 2027 des meilleurs hôpitaux spécialisés au monde établi par Newsweek
21/09/2026
RIYAD, Arabie saoudite, 21 sept. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) consolide sa position parmi les établissements de santé de référence à l’échelle mondiale en [...]
Acentra Health CEO Todd Stottlemyer Named to Virginia 500 Power List for Fifth Consecutive Year
21/09/2026
Recognition underscores the healthcare technology leader’s sustained commitment to Virginia’s business community and improved health outcomes nationwide MCLEAN, Va., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a [...]
BayCare Releases 2025 Physician and Provider Annual Report
21/09/2026
CLEARWATER, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- BayCare Health System today released Vital Impact, its 2025 Physician and Provider Annual Report, highlighting a year of clinical excellence, academic growth and [...]
Guardian Classic Welcomes Wounded Warrior Project as Official Sponsor Ahead of September 28 Charity Golf Tournament
21/09/2026
Two mission-driven nonprofit organizations team up to support active-duty, veterans, first responders and their families as the Guardian Classic enters its final days of registration and fundraising SAN DIEGO, Sept. 21 [...]
R3 Vascular Appoints Lisa Wipperman Heine to its Board of Directors
21/09/2026
Brings more than three decades of experience leading innovation across the medical technology industry MOUNTAIN VIEW, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to [...]
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
21/09/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder [...]
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
21/09/2026
Johnson & Johnson introduces the first IL-23R targeted oral peptide that can deliver skin clearance and a favourable safety profile in a once-daily pill. 1,2 ICOTYDE™ (icotrokinra) offers an innovative new option [...]
Transactions under Novonesis’ share buyback program
21/09/2026
Please read the announcement in PDF Attachment 2026_18_Share_buyback
Siemens Healthineers and Novo Join Forces to Advance Care for People Living with MASLD and MASH
21/09/2026
Tarrytown, New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- People most at risk for MASLD/MASH remain largely unaware of the disease and its wider health risks Patients facing this metabolic condition benefit from [...]
Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
21/09/2026
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb study of opamtistomig [...]
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
21/09/2026
Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
21/09/2026
By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2026
21/09/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Comprehensive Healthcare funds additional faculty position to grow Central Washington University’s graduate counseling program
21/09/2026
Ongoing collaboration addresses growing need for behavioral health professionals regionally YAKIMA, Wash., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Comprehensive Healthcare is proud to announce more than $300,000 in funding [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
21/09/2026
Déclaration de transactions sur actions propres Paris, France (21 septembre 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 28 avril 2026, EssilorLuxottica déclare que le 18 septembre [...]
EssilorLuxottica: Disclosure of transactions in own shares
21/09/2026
Disclosure of transactions in own shares Paris, France (September 21, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that [...]
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
21/09/2026
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]

Pages